KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Deffered Revenue: 2009-2024

Historic Non-Current Deffered Revenue for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $156.5 million.

  • Ionis Pharmaceuticals' Non-Current Deffered Revenue fell 37.91% to $107.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.9 million, marking a year-over-year decrease of 37.91%. This contributed to the annual value of $156.5 million for FY2024, which is 35.11% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Non-Current Deffered Revenue of $156.5 million as of FY2024, which was down 35.11% from $241.2 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $424.0 million for FY2020, and its period low was $156.5 million during FY2024.
  • Its 3-year average for Non-Current Deffered Revenue is $228.5 million, with a median of $241.2 million in 2023.
  • Data for Ionis Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY tumbled of 35.11% (in 2024) over the last 5 years.
  • Over the past 5 years, Ionis Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $424.0 million in 2020, then decreased by 17.02% to $351.9 million in 2021, then decreased by 18.22% to $287.8 million in 2022, then declined by 16.19% to $241.2 million in 2023, then plummeted by 35.11% to $156.5 million in 2024.